191 related articles for article (PubMed ID: 19238334)
1. The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC).
Strazisar M; Mlakar V; Glavac D
Cell Mol Biol Lett; 2009; 14(3):442-56. PubMed ID: 19238334
[TBL] [Abstract][Full Text] [Related]
2. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas.
Smith SL; Gugger M; Hoban P; Ratschiller D; Watson SG; Field JK; Betticher DC; Heighway J
Br J Cancer; 2004 Oct; 91(8):1515-24. PubMed ID: 15467767
[TBL] [Abstract][Full Text] [Related]
3. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
[TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.
Miura N; Nakamura H; Sato R; Tsukamoto T; Harada T; Takahashi S; Adachi Y; Shomori K; Sano A; Kishimoto Y; Ito H; Hasegawa J; Shiota G
Cancer Sci; 2006 Dec; 97(12):1366-73. PubMed ID: 17052260
[TBL] [Abstract][Full Text] [Related]
5. LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma.
Strazisar M; Mlakar V; Glavac D
Lung Cancer; 2009 Jun; 64(3):257-62. PubMed ID: 19008013
[TBL] [Abstract][Full Text] [Related]
6. Long Noncoding RNA PVT1 Promotes Non-Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression.
Wan L; Sun M; Liu GJ; Wei CC; Zhang EB; Kong R; Xu TP; Huang MD; Wang ZX
Mol Cancer Ther; 2016 May; 15(5):1082-94. PubMed ID: 26908628
[TBL] [Abstract][Full Text] [Related]
7. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC).
Dworakowska D; Jassem E; Jassem J; Peters B; Dziadziuszko R; Zylicz M; Jakóbkiewicz-Banecka J; Kobierska-Gulida G; Szymanowska A; Skokowski J; Roessner A; Schneider-Stock R
Lung Cancer; 2004 Mar; 43(3):285-95. PubMed ID: 15165086
[TBL] [Abstract][Full Text] [Related]
8. K-RAS and P53 mutations in association with COX-2 and hTERT expression and clinico-pathological status of NSCLC patients.
Strazisar M; Rott T; Glavac D
Dis Markers; 2008; 25(2):97-106. PubMed ID: 18957720
[TBL] [Abstract][Full Text] [Related]
9. COX-2 overexpression and -8473 T/C polymorphism in 3' UTR in non-small cell lung cancer.
Bhat IA; Rasool R; Qasim I; Masoodi KZ; Paul SA; Bhat BA; Ganaie FA; Aziz SA; Shah ZA
Tumour Biol; 2014 Nov; 35(11):11209-18. PubMed ID: 25113252
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of LATS2 in non-small cell lung cancer promoted the growth and motility of cancer cells.
Yao F; Liu H; Li Z; Zhong C; Fang W
Tumour Biol; 2015 Mar; 36(3):2049-57. PubMed ID: 25391426
[TBL] [Abstract][Full Text] [Related]
11. LATS2 as a poor prognostic marker regulates non-small cell lung cancer invasion by modulating MMPs expression.
Wu A; Li J; Wu K; Mo Y; Luo Y; Ye H; Mai Z; Guo K; Wang Y; Li S; Chen H; Luo W; Yang Z
Biomed Pharmacother; 2016 Aug; 82():290-7. PubMed ID: 27470365
[TBL] [Abstract][Full Text] [Related]
12. Frequent polymorphic variations but rare tumour specific mutations of the S100A2 on 1q21 in non-small cell lung cancer.
Strazisar M; Rott T; Glavac D
Lung Cancer; 2009 Mar; 63(3):354-9. PubMed ID: 18656279
[TBL] [Abstract][Full Text] [Related]
13. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis.
Feng G; Xu X; Youssef EM; Lotan R
Cancer Res; 2001 Nov; 61(21):7999-8004. PubMed ID: 11691825
[TBL] [Abstract][Full Text] [Related]
14. Low LATS2 expression is associated with poor prognosis in non-small cell lung carcinoma.
Jang SH; Oh MH; Cho H; Lee JH; Lee H; Ahn H; Kim H
Pol J Pathol; 2019; 70(3):189-197. PubMed ID: 31820862
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinicopathological significance of S100 calcium binding protein A2 in lung cancer patients of Chinese Han ethnicity.
Wang T; Liang Y; Thakur A; Zhang S; Liu F; Khan H; Shi P; Wang N; Chen M; Ren H
Clin Chim Acta; 2017 Jan; 464():118-122. PubMed ID: 27876462
[TBL] [Abstract][Full Text] [Related]
16. Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer.
Grimminger PP; Schneider PM; Metzger R; Vallböhmer D; Danenberg KD; Danenberg PV; Hölscher AH; Brabender J
Clin Lung Cancer; 2010 Mar; 11(2):114-9. PubMed ID: 20199977
[TBL] [Abstract][Full Text] [Related]
17. Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas.
Luo SY; Sit KY; Sihoe AD; Suen WS; Au WK; Tang X; Ma ES; Chan WK; Wistuba II; Minna JD; Tsao GS; Lam DC
Lung Cancer; 2014 Aug; 85(2):282-92. PubMed ID: 24976335
[TBL] [Abstract][Full Text] [Related]
18. LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1.
Zhu FY; Zhang SR; Wang LH; Wu WD; Zhao H
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8377-8390. PubMed ID: 31646568
[TBL] [Abstract][Full Text] [Related]
19. Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma.
Strazisar M; Mlakar V; Rott T; Glavac D
Cancer Invest; 2009 May; 27(4):407-16. PubMed ID: 19229701
[TBL] [Abstract][Full Text] [Related]
20. High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes.
Ibe T; Shimizu K; Nakano T; Kakegawa S; Kamiyoshihara M; Nakajima T; Kaira K; Takeyoshi I
J Surg Oncol; 2010 Jul; 102(1):11-7. PubMed ID: 20578072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
